Phentermine and topiramate extended release combination drug reduces T2DM incidences….
Type 2 diabetes along with obesity have increased over the years in the U.S. Patients have been using weight-loss medications to help with their obesity. Qsymia, a weight-loss medication that contains phentermine and topiramate, has been seen to reduce the incidence of type 2 diabetes.
This study was a 108 week randomized, double-blinded, parallel-group, placebo-controlled trail. Patients had to had either prediabetes or metabolic syndrome at the beginning of the study which was called the CONQUER trail. Then they were enrolled in the extension trail, SEQUEL. The primary endpoint was to observe weight loss from the CONQUER baseline. The secondary endpoint was to observe the annualized incidence of diabetes.
In the CONQUER trial, patients were given a once a day oral placebo, a low or high dose of the combination drug along with lifestyle-modification counseling that is based on the LEARN (lifestyle, exercise, attitudes, relationships, and nutrition) program.
The results showed a 12.1% average weight loss in the high-dose group, 10.9% in the low-dose group, and 2.5% in the placebo group. The annualized incidence rate of diabetes was 1.3 in the high-dose group, 1.8 in the low-dose group, and 6.1 in the placebo group. It can be concluded that there was an association between the drugs and risk of diabetes. The drugs showed a lower incidence rate of diabetes compared to the placebo group. It also showed a higher rate of weight loss.
- Qsymia reduces incidence of T2DM in overweight and obese patients
- Qsymia with lifestyle modifications significantly reduces weight
- High-dose drug showed 12.1% average weight loss
Diabetes Care October 2013